GlassScriptPhysician profile
Chao Ho
NPI 1629161146
$6,879.53
in general payments reported to CMS, 2019-2025
35 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $816 · 2021: $1,115 · 2022: $890 · 2023: $1,018 · 2024: $1,122 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $856.65 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $754.89 | 2019-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $713.96 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.62 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $628.66 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $442.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $368.32 | 2019-2025 | Verquvo, Steglatro, Januvia |
| Gilead Sciences, INC. | $303.69 | 2019-2025 | |
| Abbvie INC. | $255.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $239.45 | 2022-2025 | |
| Amarin Pharma, INC. | $198.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $164.50 | 2019-2022 | |
| Radius Health, INC. | $160.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $141.59 | 2019-2024 | Eliquis |
| Amgen INC. | $106.72 | 2019-2024 | Repatha, Otezla |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $104.84 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $98.69 | 2021-2024 | Linzess |
| Exact Sciences Corporation | $96.53 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.89 | 2019-2023 | Xifaxan |
| Aimmune Therapeutics, INC. | $55.31 | 2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $51.95 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $51.70 | 2023-2025 | Rexulti |
| Abbott Laboratories | $41.84 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $41.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $33.23 | 2023 | Quviviq |
| Seqirus USA INC | $27.60 | 2025 | Fluad, Flucelvax |
| Optinose US, INC. | $22.23 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $21.91 | 2025 | Zoryve |
| Amneal Pharmaceuticals LLC | $20.54 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.52 | 2024 | Givlaari |
| Phathom Pharmaceuticals, INC. | $19.00 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $16.56 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chao Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.